Updated: Jan 27
OSOYOOS, British Columbia, Jan. 26, 2021 – Way2Grow Biopharma (“Way2Grow” or “W2G”),
A private biopharma company is pleased to announce the submission of a Dealer Licence application to procure psilocybin and psilocin compounds from mushrooms as well as propagate, cultivate, harvest and distribute psychedelic mushrooms to pharmacies, clinics and other facilities for research purposes, pursuant to Part J of the Food & Drug Regulations.
Our production facility is designed to support tissue culture, micropropagation and meet organic cannabis cultivation, processing and medical sales requirements.
The approval of a Dealer Licence under Part J of the Food & Drug Regulations will enable the procurement of psilocybin and psilocin compounds as well as propagate, cultivate, harvest and distribute psychedelic mushrooms to pharmacies, clinics and other research facilities, pursuant to Part J of the Food & Drug Regulations. Way2Grow uses a refining, stabilizing and purifying organic methodology to standardize growth plans in addition to developing a sequenced spore library for a variety of psilocybin species.
Way2Grow Biopharma's expansion plan includes the expansion of its research laboratory, the addition of controlled rooms for the cultivation, production, extraction and formulation of Psilocybin Mushrooms, and the addition of a medical dispensary in Osoyoos, B.C.
Way2Grow Biopharma (W2G) is a biopharma company with a mission to Improve Health & Wellness by Growing, Standardizing & Supplying Medical Innovation.